Do interruptions to the continuity of methadone maintenance treatment in specialist addiction settings increase the risk of drug-related poisoning deaths? A retrospective cohort study.


Journal

Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118

Informations de publication

Date de publication:
10 2020
Historique:
received: 23 09 2019
revised: 02 12 2019
accepted: 05 02 2020
pubmed: 9 2 2020
medline: 20 4 2021
entrez: 9 2 2020
Statut: ppublish

Résumé

To examine the risk of mortality associated with interruptions to the continuity of methadone maintenance treatment (MMT), including transfers between services, in opioid-dependent individuals attending specialist addiction services. Retrospective cohort study using addiction services and primary care dispensing records, the National Methadone Register and National Drug-Related Death Index (NDRDI). Geographically defined population in Dublin, Ireland. A total of 2899 people prescribed and dispensed methadone in specialist addiction services between January 2010 and December 2015. There were five exposure groups: weeks 1-4 following transfer between treatment providers; weeks 1-4 out of treatment; weeks 5-52 out of treatment; weeks 1-4 of treatment initiation; and weeks 5+ of continuous treatment (reference category). Primary outcome: drug-related poisoning (DRP) deaths. Secondary outcome: all-cause mortality (ACM). Mortality rates calculated by dividing number of deaths (DRP; ACM) in exposure groups by person-years exposure. Unadjusted and adjusted Poisson regression (covariates age, sex, incarceration, methadone dose and comorbidities) estimated differences in mortality rates. There were 154 ACM deaths, 55 (35.7%) identified as DRP deaths. No deaths were observed in the first month following transfer between treatment providers. The risk of DRP mortality was highest in weeks 1-4 out of treatment [adjusted relative risk (aRR = 4.04, 95% confidence interval (CI) = 1.43-11.43, P = 0.009] and weeks 1-4 of treatment initiation (ARR = 3.4, 95% CI = 1.2-9.64, P = 0.02). Similarly, risk of ACM was highest in weeks 1-4 out of treatment (ARR = 11.78, 95% CI = 7.73-17.94, P < 0.001), weeks 1-4 of treatment initiation (aRR = 5.11, 95% CI = 2.95-8.83, P < 0.001) and weeks 5-52 off treatment (aRR = 2.04, 95% CI = 1.2-3.47, P = 0.009). Interruptions to the continuity of methadone maintenance treatment by treatment provider do not appear to be periods of risk for drug-related poisoning or all-cause mortality deaths. Risk of drug related poisoning and all-cause mortality deaths appears to be greatest during the first 4 weeks of treatment initiation/re-initiation and after treatment cessation.

Identifiants

pubmed: 32034837
doi: 10.1111/add.15004
pmc: PMC7540578
doi:

Substances chimiques

Narcotics 0
Methadone UC6VBE7V1Z

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1867-1877

Informations de copyright

© 2020 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.

Références

Addiction. 2015 Jun;110(6):996-1005
pubmed: 25644938
Harm Reduct J. 2019 Jan 17;16(1):5
pubmed: 30654803
Addiction. 2018 Aug;113(8):1461-1476
pubmed: 29672985
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
BMC Fam Pract. 2018 Jun 30;19(1):103
pubmed: 29960593
Lancet Psychiatry. 2015 Oct;2(10):901-8
pubmed: 26384619
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD002209
pubmed: 19588333
Addiction. 2018 May;113(5):946-951
pubmed: 29179255
Addiction. 2016 Jan;111(1):73-82
pubmed: 26234389
BMJ. 2018 Nov 14;363:k4524
pubmed: 30429122
Addiction. 2017 Aug;112(8):1408-1418
pubmed: 28160345
Addiction. 2008 Sep;103(9):1484-92
pubmed: 18636999
Addiction. 2009 Jul;104(7):1193-200
pubmed: 19563562
BMJ. 2010 Oct 26;341:c5475
pubmed: 20978062
Addiction. 2010 Sep;105(9):1545-54
pubmed: 20579009
PLoS One. 2015 Oct 23;10(10):e0140995
pubmed: 26495843
BMJ. 2009 Jun 16;338:b2225
pubmed: 19535400
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Br J Clin Pharmacol. 2019 Jan;85(1):202-215
pubmed: 30338545
Addiction. 2007 Dec;102(12):1954-9
pubmed: 18031430
Drug Alcohol Depend. 2006 Jan 4;81(1):55-61
pubmed: 15993552
Addiction. 2002 Aug;97(8):993-1001
pubmed: 12144602
Addiction. 2009 Aug;104(8):1363-72
pubmed: 19549053
BMJ Open. 2018 Apr 13;8(4):e021122
pubmed: 29654048
Drug Alcohol Depend. 2009 Nov 1;105(1-2):9-15
pubmed: 19608355
BMJ. 2010 Jul 01;341:c3172
pubmed: 20595255
Addiction. 2014 Aug;109(8):1306-17
pubmed: 24612249
Addiction. 2020 Oct;115(10):1867-1877
pubmed: 32034837
BMJ. 2013 Jan 30;346:f174
pubmed: 23372174
Drug Alcohol Depend. 2017 Apr 01;173:126-131
pubmed: 28232249
Clin Infect Dis. 2015 Oct 1;61(7):1157-65
pubmed: 26113656
J Subst Abuse Treat. 2011 Oct;41(3):252-60
pubmed: 21696913
BMJ Open. 2019 Jun 4;9(6):e024747
pubmed: 31167862

Auteurs

Louise Durand (L)

School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.

Denis O'Driscoll (D)

HSE Addiction Services, Dublin, Ireland.

Fiona Boland (F)

HRB Centre for Primary Care Research, Royal College of Surgeons in Ireland, Dublin, Ireland.

Eamon Keenan (E)

HSE National Social Inclusion Office, Stewarts Hospital, Dublin, Ireland.

Benedict K Ryan (BK)

School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.

Joseph Barry (J)

Department of Public Health and Primary Care, Trinity College Dublin, Ireland.

Kathleen Bennett (K)

Division of Population Health Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.

Tom Fahey (T)

Department of General Practice and HRB Centre for Primary Care Research, Royal College of Surgeons in Ireland, Dublin, Ireland.

Gráinne Cousins (G)

School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH